According to our (Global Info Research) latest study, the global Cardiac Biomarker POCT Diagnostic Device market size was valued at US$ 247 million in 2025 and is forecast to a readjusted size of US$ 382 million by 2032 with a CAGR of 6.2% during review period.
The Cardiac Biomarker POCT Diagnostic Device is designed for emergency departments, chest pain centers, intensive care units, cardiology outpatient clinics, primary care, and pre-hospital emergency use. It utilizes fluorescence immunoassay, chemiluminescence, and microfluidic technologies to measure cardiac injury markers including cTnI, hs-cTnI, cTnT, CK-MB, and myoglobin, as well as heart failure biomarkers BNP and NT-proBNP. Upstream materials include highly specific monoclonal antibodies, fluorescent labels, microfluidic chips, and dedicated consumables. The main customers are hospitals, emergency and chest pain centers, ICUs, cardiology clinics, primary care facilities, and pre-hospital emergency services worldwide. In 2025, global production capacity is approximately 26,500 units, with actual sales around 21,380 units, an average ex-factory price of 11,200 USD per unit, and a gross margin range of 38%–50%.
The global market for cardiac biomarker POCT diagnostic devices exhibits a multi-layered competitive structure, with high-end companies in North America, Europe, and Japan coexisting with mid-tier manufacturers in China and South Korea. Emergency departments, chest pain centers, and ICUs remain core application areas. Platforms have evolved from single-marker testing to high-sensitivity troponin, multi-marker panels, microfluidic, and fluorescence immunoassay technologies, creating a complete ecosystem of analyzers and reagent consumables. Manufacturers establish recurring revenue and customer stickiness through consumable binding, hospital data integration, and workflow coordination. Chinese and Korean companies expand market share through cost control, rapid product iteration, and export channels, while Western and Japanese leaders maintain technological and brand advantages in high-end hospital settings, also pushing the integration of high-sensitivity assays and connected data systems.
Future trends indicate continuous growth in platform-based, multi-marker testing and high-sensitivity troponin penetration. Next-generation devices will increasingly feature microfluidic chips, dry fluorescence assays, automated operation systems, portability, and networked functionality. Information integration and data management capabilities are becoming critical for platform competitiveness, driving optimization of emergency workflows, remote monitoring, and differentiated clinical decision support. Regionally, Chinese and Korean firms are rapidly expanding mid-tier and export markets, while Western and Japanese companies maintain leadership in high-end hospitals, forming a globally multi-tiered, regionally complementary market. Clinical validation and standardization of new technologies will further enhance device reliability and physician acceptance, supporting sustained market growth.
Market growth is primarily driven by strong clinical demand for rapid and high-precision testing. High-sensitivity assays and multi-marker panels optimize acute myocardial infarction triage, heart failure evaluation, and critical patient monitoring. Technological iteration and new product development not only enhance platform capabilities but also provide opportunities for market share expansion and improved gross margins. Downstream customers include hospitals, emergency and chest pain centers, ICUs, cardiology outpatient clinics, primary care facilities, and pre-hospital emergency services. Companies achieve sustainable revenue through device-consumable integration, client management, and service upgrades, establishing long-term competitive barriers in clinical protocols and hospital workflows.
Obstacles include stringent regulatory and clinical validation requirements, hospital procurement pacing, and constraints from reimbursement and payment systems. Low-sensitivity or single-marker platforms may be displaced by high-sensitivity, multi-marker, automated, and connected platforms. Regional differences in policy, regulation, and clinical adoption may also influence market growth. A company's R&D capabilities, clinical support system, marketing strategies, and service network directly determine its competitive position. Technological innovation and comprehensive service systems remain critical to overcoming market barriers and driving sustainable industry development.
This report is a detailed and comprehensive analysis for global Cardiac Biomarker POCT Diagnostic Device market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cardiac Biomarker POCT Diagnostic Device market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Cardiac Biomarker POCT Diagnostic Device market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Cardiac Biomarker POCT Diagnostic Device market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Cardiac Biomarker POCT Diagnostic Device market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cardiac Biomarker POCT Diagnostic Device
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cardiac Biomarker POCT Diagnostic Device market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Abbott Laboratories, QuidelOrtho Corporation, Radiometer Medical, Siemens Healthineers, PHC Holdings, Guangzhou Wondfo Biotech, Getein Biotech, Boditech Med, SD BIOSENSOR, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Cardiac Biomarker POCT Diagnostic Device market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Fluorescence Immunoassay
Chemiluminescence Immunoassay
Other
Market segment by Form
Handheld
Benchtop
Other
Market segment by Cardiac Biomarker
Troponin-focused
Natriuretic Peptide-focused
Other
Market segment by Application
Hospital
Clinic
Others
Major players covered
Roche
Abbott Laboratories
QuidelOrtho Corporation
Radiometer Medical
Siemens Healthineers
PHC Holdings
Guangzhou Wondfo Biotech
Getein Biotech
Boditech Med
SD BIOSENSOR
Lepu Medical Technology
Humasis
NanoEntek
Xiamen Biotime Biotechnology
Nanjing Lansion Biotechnology
Shenzhen Micropoint Biotechnologies
Shijiazhuang Hipro Biotechnology
AEHEALTH
Guangzhou KOFA Biotechnology
Response Biomedical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cardiac Biomarker POCT Diagnostic Device product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Cardiac Biomarker POCT Diagnostic Device, with price, sales quantity, revenue, and global market share of Cardiac Biomarker POCT Diagnostic Device from 2021 to 2026.
Chapter 3, the Cardiac Biomarker POCT Diagnostic Device competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cardiac Biomarker POCT Diagnostic Device breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Cardiac Biomarker POCT Diagnostic Device market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Cardiac Biomarker POCT Diagnostic Device.
Chapter 14 and 15, to describe Cardiac Biomarker POCT Diagnostic Device sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Cardiac Biomarker POCT Diagnostic Device. Industry analysis & Market Report on Cardiac Biomarker POCT Diagnostic Device is a syndicated market report, published as Global Cardiac Biomarker POCT Diagnostic Device Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Cardiac Biomarker POCT Diagnostic Device market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.